Zheng L, Wang Y, Liu Z, Wang Z, Tao C, Wu A
Cancer Med. 2024; 13(7):e7043.
PMID: 38572921
PMC: 10993708.
DOI: 10.1002/cam4.7043.
Pessino G, Scotti C, Maggi M, Immuno-Hub Consortium
Cancers (Basel). 2024; 16(5).
PMID: 38473265
PMC: 10931414.
DOI: 10.3390/cancers16050901.
Coffin P, He A
Int J Mol Sci. 2023; 24(17).
PMID: 37686079
PMC: 10487618.
DOI: 10.3390/ijms241713274.
Maloberti T, De Leo A, Sanza V, Gruppioni E, Altimari A, Riefolo M
World J Gastroenterol. 2022; 28(25):2854-2866.
PMID: 35978866
PMC: 9280731.
DOI: 10.3748/wjg.v28.i25.2854.
Kotiyal S, Evason K
Cancers (Basel). 2021; 13(16).
PMID: 34439356
PMC: 8393605.
DOI: 10.3390/cancers13164202.
Abnormal function of telomere protein TRF2 induces cell mutation and the effects of environmental tumor‑promoting factors (Review).
Wang Z, Wu X
Oncol Rep. 2021; 46(2).
PMID: 34278498
PMC: 8273685.
DOI: 10.3892/or.2021.8135.
Distinct Patterns of HBV Integration and Alterations between in Tumor and Non-Tumor Tissue in Patients with Hepatocellular Carcinoma.
Jang J, Kim H, Kim J, Lee S, Han J, Sung P
Int J Mol Sci. 2021; 22(13).
PMID: 34209079
PMC: 8268258.
DOI: 10.3390/ijms22137056.
Recurrent HBV Integration Targets as Potential Drivers in Hepatocellular Carcinoma.
Lin S, Zhang A, Lian J, Wang J, Chang T, Lin Y
Cells. 2021; 10(6).
PMID: 34071075
PMC: 8224658.
DOI: 10.3390/cells10061294.
Significance of Genetic Alterations and Telomere Length in Hepatocellular Carcinoma.
Jang J, Kim J, Kim H, Tak K, Lee S, Nam H
Cancers (Basel). 2021; 13(9).
PMID: 33946181
PMC: 8125722.
DOI: 10.3390/cancers13092160.
Persistence of intrahepatic hepatitis B virus DNA integration in patients developing hepatocellular carcinoma after hepatitis B surface antigen seroclearance.
Jang J, Kim J, Kim H, Tak K, Nam H, Sung P
Clin Mol Hepatol. 2020; 27(1):207-218.
PMID: 33317255
PMC: 7820213.
DOI: 10.3350/cmh.2020.0115.
Poly(U) binding splicing factor 60 promotes renal cell carcinoma growth by transcriptionally upregulating telomerase reverse transcriptase.
Long Q, Hua Y, He L, Zhang C, Sui S, Li Y
Int J Biol Sci. 2020; 16(15):3002-3017.
PMID: 33061812
PMC: 7545719.
DOI: 10.7150/ijbs.45115.
Telomeres and Telomerase in the Development of Liver Cancer.
In der Stroth L, Tharehalli U, Gunes C, Lechel A
Cancers (Basel). 2020; 12(8).
PMID: 32722302
PMC: 7464754.
DOI: 10.3390/cancers12082048.
Circulating tumor DNA as an emerging liquid biopsy biomarker for early diagnosis and therapeutic monitoring in hepatocellular carcinoma.
Wu X, Li J, Gassa A, Buchner D, Alakus H, Dong Q
Int J Biol Sci. 2020; 16(9):1551-1562.
PMID: 32226301
PMC: 7097921.
DOI: 10.7150/ijbs.44024.
The use of cell free DNA in the diagnosis of HCC.
Banini B, Sanyal A
Hepatoma Res. 2019; 5.
PMID: 31673629
PMC: 6822275.
DOI: 10.20517/2394-5079.2019.30.
Profiling of LINE-1-Related Genes in Hepatocellular Carcinoma.
Honda T, Rahman M
Int J Mol Sci. 2019; 20(3).
PMID: 30717368
PMC: 6387036.
DOI: 10.3390/ijms20030645.
Liquid biopsies for hepatocellular carcinoma.
Su Y, Kim A, Jain S
Transl Res. 2018; 201:84-97.
PMID: 30056068
PMC: 6483086.
DOI: 10.1016/j.trsl.2018.07.001.
Telomere Maintenance Mechanisms in Cancer.
Gaspar T, Sa A, Lopes J, Sobrinho-Simoes M, Soares P, Vinagre J
Genes (Basel). 2018; 9(5).
PMID: 29751586
PMC: 5977181.
DOI: 10.3390/genes9050241.
Mechanisms of human telomerase reverse transcriptase (hTERT) regulation: clinical impacts in cancer.
Leao R, Apolonio J, Lee D, Figueiredo A, Tabori U, Castelo-Branco P
J Biomed Sci. 2018; 25(1):22.
PMID: 29526163
PMC: 5846307.
DOI: 10.1186/s12929-018-0422-8.
Clinicopathological characteristics of TERT promoter mutation and telomere length in hepatocellular carcinoma.
Lee H, Park T, Jang S, Park S, Park W, Jung S
Medicine (Baltimore). 2017; 96(5):e5766.
PMID: 28151853
PMC: 5293416.
DOI: 10.1097/MD.0000000000005766.
Genetic alterations in hepatocellular carcinoma: An update.
Niu Z, Niu X, Wang W
World J Gastroenterol. 2016; 22(41):9069-9095.
PMID: 27895396
PMC: 5107590.
DOI: 10.3748/wjg.v22.i41.9069.